Literature DB >> 8475795

Bone mineral density and parameters of bone metabolism in patients with acromegaly.

H Kotzmann1, P Bernecker, P Hübsch, P Pietschmann, W Woloszczuk, T Svoboda, G Geyer, A Luger.   

Abstract

To assess the effect of chronically elevated plasma growth hormone (GH) levels on bone metabolism and bone mineral density (BMD), 16 patients (10 females and 6 males) with a mean age of 49.1 +/- 13.2 years (range 33-68) with active acromegaly were studied and compared to a control group of 16 sex- and age-matched subjects. BMD of the lumbar spine and two different sites of the proximal femur were measured by dual-energy x-ray absorptiometry (Norland XR-26). In the acromegalic patients the mean plasma GH concentration was 30.1 +/- 11.1 micrograms/liter, and the mean plasma somatomedin C (SMC) concentration was 6.5 +/- 1.5 U/liter. Mean serum osteocalcin (OC) levels (14.3 +/- 1.1 versus 7.2 +/- 0.4 ng/ml, p < 0.001) as well as the urinary hydroxyproline excretion (OHP; 8.8 +/- 1.4 versus 2.7 +/- 0.3 mg, p < 0.0001) were significantly higher in the acromegalic patients than in the control subjects. In the acromegalic patients BMD was significantly elevated in the two examined regions of the proximal femur, that is, the femoral neck (1.06 +/- 0.05 versus 0.86 +/- 0.03 g/cm2, p < 0.05) and Ward's triangle (0.92 +/- 0.06 versus 0.76 +/- 0.03 g/cm2, p < 0.02), whereas the BMD of the lumbar spine was not significantly different from that of control subjects. Among the patients with acromegaly a significant positive correlation between serum OC concentrations, on the one hand, and urinary OHP excretion (r = 0.7, p < 0.004) as well as BMD in the proximal femur (r = 0.64, p < 0.007), on the other hand, could be observed.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8475795     DOI: 10.1002/jbmr.5650080410

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  20 in total

Review 1.  Bone mineral density in acromegaly: does growth hormone excess protect against osteoporosis?

Authors:  I Chiodini; V Trischitta; V Carnevale; A Liuzzi; A Scillitani
Journal:  J Endocrinol Invest       Date:  2001-04       Impact factor: 4.256

2.  Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine.

Authors:  M J Kayath; J G Vieira
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

3.  Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function.

Authors:  Marek Bolanowski; Jacek Daroszewski; Marek Medraś; Beata Zadrozna-Sliwka
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

4.  Nonlinear association between bone mineral density and all-cause mortality: the Dong-gu study.

Authors:  C K Choi; S -S Kweon; Y -H Lee; H -S Nam; K -S Park; S -Y Ryu; S -W Choi; S A Kim; M -H Shin
Journal:  Osteoporos Int       Date:  2018-07-16       Impact factor: 4.507

5.  Exon 3-deleted growth hormone receptor isoform is not related to worse bone mineral density or microarchitecture or to increased fracture risk in acromegaly.

Authors:  J Pontes; M Madeira; C H A Lima; L L Ogino; F de Paula Paranhos Neto; L M C de Mendonça; M L F Farias; L Kasuki; M R Gadelha
Journal:  J Endocrinol Invest       Date:  2019-08-07       Impact factor: 4.256

6.  The effects of high serum growth hormone and IGF-1 levels on bone mineral density in acromegaly.

Authors:  S Tuzcu; Ş A Durmaz; A Carlıoğlu; Z Demircan; A Tuzcu; C Beyaz; A Tay
Journal:  Z Rheumatol       Date:  2017-10       Impact factor: 1.372

7.  Long-term effects of octreotide on markers of bone metabolism in acromegaly: evidence of increased serum parathormone concentrations.

Authors:  P Legovini; E De Menis; F Breda; D Billeci; A Carteri; P Pavan; N Conte
Journal:  J Endocrinol Invest       Date:  1997-09       Impact factor: 4.256

8.  Bone mineral density and circulating cytokines in patients with acromegaly.

Authors:  S Longobardi; C Di Somma; F Di Rella; N Angelillo; D Ferone; A Colao; B Merola; G Lombardi
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

9.  Alterations in body composition in acromegaly.

Authors:  Laurence Katznelson
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 10.  Growth hormone, insulin-like growth factors, and the skeleton.

Authors:  Andrea Giustina; Gherardo Mazziotti; Ernesto Canalis
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.